A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer).
Ellis Glenn Levine
Research Funding - Department of Defense
Andres Forero
Research Funding - TRACON Pharma
Tracy O'Connor
No relevant relationships to disclose
Ben K. Seon
Consultant or Advisory Role - TRACON Pharma (U)
Research Funding - Department of Defense
Manoj A Jivani
Stock Ownership - TRACON Pharma
Bonne J. Adams
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma
Charles P. Theuer
Employment or Leadership Position - TRACON Pharma
Stock Ownership - TRACON Pharma